|Rapid Review Complete
|In combination with LDAC (low-dose cytarabine), for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia in adult patients who are not candidates for standard induction chemotherapy.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Reimbursement is not recommended at this time, due to a lack of evaluable evidence*
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.